AbbVie ABBV Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Product | ||||||
| All other | $2.91B-7.3% | $3.13B-4.1% | $3.27B-2.0% | $3.33B-5.8% | $3.54B+16.8% | |
| Botox Cosmetic | $2.71B+4.3% | $2.6B+1.2% | $2.57B-1.3% | $2.61B-1.4% | $2.64B-2.8% | |
| Botox Therapeutic | $3.91B+3.8% | $3.77B+3.2% | $3.65B+3.9% | $3.52B+3.4% | $3.4B+3.6% | |
| Elahere | $709M+2.8% | $690M+5.2% | $656M+5.0% | $625M+5.2% | $594M+24.0% | |
| Epkinly | $303M+11.8% | $271M+17.8% | $230M+12.7% | $204M+20.0% | $170M+16.4% | |
| Humira | $4.11B-9.5% | $4.54B-8.8% | $4.98B-19.9% | $6.21B-20.8% | $7.84B-12.8% | |
| Imbruvica | $2.69B-6.3% | $2.87B-5.8% | $3.05B-3.9% | $3.17B-2.4% | $3.25B-3.0% | |
| Juvederm Collection | $994M+0.1% | $993M-2.9% | $1.02B-0.5% | $1.03B-7.5% | $1.11B-5.6% | |
| Linzess | $1.04B+14.9% | $907M-6.0% | $965M+10.5% | $873M+4.4% | $836M-12.4% | |
| Mavyret | $1.36B+3.4% | $1.32B+2.6% | $1.28B+0.8% | $1.27B+0.5% | $1.27B-3.3% | |
| Other Aesthetics | $1.24B-2.3% | $1.27B-0.9% | $1.28B-0.5% | $1.28B+0.7% | $1.28B-0.3% | |
| Other Neuroscience | $273M-9.9% | $303M-2.9% | $312M-3.1% | $322M-2.1% | $329M+37.7% | |
| Qulipta | $1.14B+9.9% | $1.04B+9.2% | $949M+13.4% | $837M+16.3% | $720M+9.4% | |
| Rinvoq | $8.71B+4.8% | $8.3B+7.0% | $7.76B+7.9% | $7.19B+9.1% | $6.6B+10.5% | |
| Skyrizi | $18.62B+6.0% | $17.56B+7.5% | $16.33B+10.1% | $14.83B+12.9% | $13.14B+12.1% | |
| Ubrelvy | $1.37B+7.8% | $1.27B+2.9% | $1.24B+7.4% | $1.15B+10.3% | $1.04B+3.7% | |
| Venclexta | $2.9B+3.8% | $2.79B+2.0% | $2.74B+1.8% | $2.69B+2.1% | $2.63B+2.0% | |
| Vraylar | $3.76B+3.9% | $3.62B+2.8% | $3.52B+1.7% | $3.46B+3.8% | $3.34B+2.2% | |
| Vyalev | $620M+28.6% | $482M+40.5% | $343M+47.2% | $233M+52.3% | $153M+54.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
